BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in
the metastatic setting. Although RAF inhibitors such as vemurafenib (PLX4032) have proven …

BRAF mutations occur in approximately 10% of colorectal cancers. Although RAF inhibitor
monotherapy is highly effective in BRAF-mutant melanoma, response rates in BRAF-mutant …

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in
approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers …

Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …

Abstract BRAF V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due
to feedback reactivation of receptor tyrosine kinase signaling. Combined RAF and EGFR …

The protein kinase BRAF is a key component of the RAS–RAF signaling pathway which
plays an important role in regulating cell proliferation, differentiation, and survival. Mutations …

RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant
colorectal cancer. To gain additional insights into this difference, we performed a genome …

Oncogenic BRAF mutations are found in several tumor types, including melanomas and
colorectal cancers. Tumors with BRAF mutations have increased mitogen-activated protein …

Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal
cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma …

Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …